Pauline Brice
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 141 publications
Acceptability and feasibility of post-treatment fertility preservation in women previously treated for hematological diseases.
Journal: Haematologica
Published: October 23, 2025
Should adolescents and young adults with Hodgkin lymphoma be treated as children or adults?
Journal: British journal of haematology
Published: November 07, 2024
One-Day Brentuximab-Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma.
Journal: Hematological oncology
Published: September 19, 2024
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.
Journal: The Lancet. Oncology
Published: July 18, 2024
Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.
Journal: Haematologica
Published: December 15, 2023
Management of Hodgkin Lymphoma during pregnancy, review of the literature and description of an homogenous expectative attitude associated with excellent outcome.
Journal: Critical reviews in oncology/hematology
Published: October 24, 2023
Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.
Journal: British journal of haematology
Published: February 06, 2023
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
Journal: Lancet (London, England)
Published: August 30, 2022
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Journal: Leukemia & lymphoma
Published: August 17, 2022
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 10, 2022
Last Updated: 09/26/2026